G.V. Prasad has spent over thirty years at the helm of Dr. Reddy's Laboratories — long enough to know where the opportunities were missed and where the potential and challenges lie. In a candid conversation with ET’s pharma editor Vikas Dandekar on Corner Office Conversation, the Co-Chairman and Managing Director pulls no punches: India is the generic pharmacy of the world, not the pharmacy of the world, and that distinction matters. He reflects on regulatory crises weathered, acquisitions never made, and an innovation pipeline that remained perpetually underfunded. On AI, he is deliberately unsentimental — helpful at the margins, not yet transformational. What he does believe in, firmly and urgently, is Dr. Reddy's next act: a decisive pivot from incremental generics to innovation-led growth, with a hard target and a ticking clock.
You will be redirected in 10 seconds.